column

AVIEW NeuroCAD Innovation's achievements and the expansion of hospitals that have adopted it

 Wonseok Ryu, New Business Development Team
Wonseok Ryu, New Business Development Team
Registration date2025. 01. 31

As a sales representative for the AVIEW LCS PLUS sales team of the Domestic Business Team, I would like to share my thoughts on what I felt at the sales site in 2024 and what I am feeling as I prepare to develop the business of our products in the New Business Development Team in 2025. It is not different from what other representatives of the Domestic Business Division feel, but Core Line Soft's domestic sales in 2024 began with high expectations in terms of sales after going public in September 2023.

 


 

Among the companies listed on KOSDAQ with AI technology, JKL, VUNO, Lunit, and DEEPNOID (listed in order of listing time) are recognized as companies that have been introduced to hospitals by radiology departments that have used the products in actual clinical settings and have requested the products to be introduced to their hospitals. The interest in the products of these companies has been high, not only from radiology departments that have used the products or learned about the technology, but also from major stakeholders in the hospital sales field.

Among the AI companies currently listed, it is considered the best company for analyzing CT images, and its main product is being supplied to Kangbuk Samsung Hospital, and major university hospitals such as Yeouido St. Mary's Hospital, Bucheon St. Mary's Hospital, Chungbuk National University Hospital, Changwon Gyeongsang National University Hospital, etc. have decided to purchase it, and it is expected to be on track in 2024. In addition, the news that VUNO's DeepCas, which was selected as a new medical technology, was introduced in hospitals and received good reviews in 2023, raising hospitals' expectations for non-reimbursable revenue, and the news that JLK's stroke diagnosis AI solution was selected as an innovative medical technology, as well as the fact that the company's cerebral hemorrhage AI solution was also selected as an innovative medical technology, raised expectations for 2024 as administrative procedures were well prepared and the company was able to receive non-reimbursable fees for its emergency medicine and cerebral hemorrhage AI solutions from January 2024.

 


 

AVIEW NeuroCAD, which was selected as an innovative medical technology, is an emergency medicine and cerebral hemorrhage emergency diagnosis support program. Like the stroke emergency diagnosis support AI program of JLK, hospitals are requesting seminars to review the comparative introduction, and 16 hospitals, including Ilsan Paik Hospital, Gumi Cha Hospital, Hwahong Hospital, and Sejong Chungnam National University Hospital, have completed their applications for the use of the product.
 

 

This made 2024 a year of positive expectations for Coreline Soft and the domestic business team responsible for sales. However, dark clouds began to appear little by little. In early 2024, the government unexpectedly announced the capacity of medical schools, which led to a strike by residents at major university hospitals and increased deficits at major hospitals, causing delays in the purchase orders that had been prepared in the first half of the year. To make matters worse, hospitals that had introduced innovative medical technologies that had been highly anticipated experienced internal problems with the creation of consent forms, slowing the sales of the products that had been expected.

But as they say, a crisis is an opportunity. Coreline Soft's overseas business team announced good news that the lung cancer screening business, which was being prepared in various European countries, had achieved tangible results. They also announced that the purchase of RT ACS products, which had been on hold for a long time, had been completed, and that hospitals that had been preparing for the AI voucher project in 2024 had finished with good results. At the KALC Lung Cancer Conference, which I participated in again after a long absence at the end of 2024, I introduced AVIEW COPD ILA ILD to various professors in the fields of respiratory medicine, thoracic surgery, radiation oncology, nuclear medicine, pathology, and pain medicine, in addition to the departments of radiology and emergency medicine that I had previously introduced. This gave me the opportunity to hear about the content required by various departments and to rethink the direction of our domestic business from various angles.

 
 

The introduction of innovative medical technologies, which had been slowed down due to various reasons, was also accelerated. With the November announcement of the hospital reimbursement rates, the National Health Insurance Service (NHIS) and the National Evidence-based Healthcare Collaborating Agency (NECA) signed an agreement, and the sales performance of the leading hospitals was shared, the number of hospitals that introduced AVIEW NEURO CAD at the end of 2024 exceeded 30.

Coreline Soft's sales offices are once again thriving, and there is good news that hospitals that have used the product in Korea are opening a medical examination center in Hanoi, Vietnam, and are considering using the excellent CHEST AI solution, which has been proven to be effective in the Korean medical field, in Vietnam.

Core Line Soft, which is now running beyond Korea to Europe and the world, is preparing for a new attempt.

In the medical examination market, we are preparing to create a new market by combining various solutions developed by Coreline Soft with the diagnostic support programs of radiology and diagnostic reading specialists, as well as the results that medical examination patients, who are customers of the medical examination market, can receive after undergoing a CT scan.

It is not easy to visit major university hospitals and general hospitals to meet radiologists, who are the main customers of our products, without an appointment. In particular, the reading rooms are often located in places that are difficult to find even within the hospital, and even if you enter the reading room, it is very difficult to meet the radiologists hidden behind the darkroom curtains. When I visit a company without receiving a request for a visit and recommend them to use the product, it means that I am confident in the product's capabilities. I have been in marketing sales for 20 years and have suggested many products, but the Coreline Soft AVIEW product I am currently proposing is more technologically advanced than any of the products I have sold in the past. That's why I'm confident in offering a demo and don't mind the hassle of product integration. I'm sure that those who have used it once will feel the appeal of Coreline Soft AVIEW, and that feeling will soon develop into purchasing power.

 

 

Since joining Coreline Soft's domestic business division, I always wear my Coreline Soft name tag on my chest when I am outside the office. When the hospital you visit asks, “How did you get here?” show them your name tag and say, “I'm here from Coreline Soft, the world's No. 1 CHEST CT AI solution.” “We are conducting a national lung cancer screening, and can we meet the hospital director or the head of the CHEST CT reading department?” When we say this, they usually cooperate with us to meet the main customers we need to meet.

 


 

There is nothing more satisfying than selling a good product to a salesperson. The power to confidently make on-site proposals comes from our product strength, and we are continuing to expand it through the use experience of those who recognize the true value of our products.

In 2024, we have faced many challenges, but we are overcoming them together and will move forward step by step in the direction we believe is right. In the new year of 2025, Coreline Soft is going to be a success. And the new sales manager, Ryu, who is starting a new job in the strategy department, is also going to be a success!

We will be successful. We believe that and we are going to be a success today, too.

#Business_Develop

#LCS

#NeuroCAD

#Domestic Business Division

#Domestic Sales

#New Business Development Team

#Emergency Medicine

#Radiology

#Innovative Medical Technology

#Image Interpretation

Contact

Please leave your inquiry if you have any questions regarding our products, recruitment, investment, or any other matters.

Contact us